What is General Proximity?
General Proximity operates at the cutting edge of biotechnology, having developed the first generalized, mechanism-agnostic, proximity discovery engine. The company's core innovation lies in its ability to map genomes that code for thousands of intricate molecular machines, specifically effector proteins. These proteins are essential for regulating diverse biological processes, including chaperone functions, adaptor protein interactions, and trafficking mechanisms.
Furthermore, the company's platform provides deep insights into post-translational modification (PTM) readers, writers, and erasers. By deciphering these intricate biological codes, General Proximity is creating a foundational layer for future therapeutic and diagnostic breakthroughs. This technological architecture positions the company as a critical player in the evolving landscape of molecular biology and precision medicine.
How much funding has General Proximity raised?
General Proximity has raised a total of $16M across 1 funding round:
Angel/Seed
$16M
Angel/Seed (2025): $16M with participation from The Rock Creek Group, Y Combinator, and Felicis Ventures
Key Investors in General Proximity
The Rock Creek Group
A global investment firm focused on integrating innovation into investment strategies to promote sustainability and long-term growth.
Y Combinator
A premier startup accelerator and seed funding provider known for identifying and nurturing high-growth technology ventures.
Felicis Ventures
A Menlo Park-based venture capital firm that supports early and growth-stage technology companies across diverse sectors including AI and fintech.
What's next for General Proximity?
With the recent capital injection, General Proximity is poised to transition from its foundational development phase into a more aggressive scaling and application-focused stage. The strategic roadmap involves expanding the utility of its proximity discovery engine to address high-impact biological challenges. By scaling its research operations and enhancing its computational capabilities, the company intends to translate its molecular insights into actionable therapeutic targets.
The focus will remain on refining the effector protein mapping process, ensuring that the platform remains the industry standard for understanding PTM dynamics. As the company matures, it will likely seek further strategic partnerships to integrate its discovery engine into broader drug development pipelines, thereby maximizing the commercial and clinical impact of its proprietary technology.
